Alterity Therapeutics Ltd Share Price Australian S.E.
Stocks
AU000000PBT9
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 83.69M 72.54M 68.01M 62.01M 117M 7.99B 119M 801M 313M 4B 314M 307M 13.34B | P/E 2026 * |
-0.42x | P/E 2027 * | -0.42x |
|---|---|---|---|---|---|
| Enterprise Value | 38.5M 33.38M 31.29M 28.53M 53.68M 3.67B 54.54M 368M 144M 1.84B 145M 141M 6.14B | EV / Sales 2026 * |
11.7x | EV / Sales 2027 * | 17.1x |
| Free-Float |
91.85% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alterity Therapeutics Ltd
| 1 day | +2.04% |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 06/01/2021 |
Abby Macnish
DFI | Director of Finance/CFO | - | 29/09/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 28/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 07/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 20/11/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.04% | +2.08% | - | - | 82.16M | |
| -1.97% | -1.92% | +1.74% | +13.56% | 49.24B | |
| +0.08% | -1.59% | +460.49% | +572.97% | 43.3B | |
| -2.62% | -0.45% | +11.96% | +69.85% | 40.48B | |
| -1.03% | -0.06% | +25.96% | +8.38% | 39.75B | |
| -0.50% | +3.08% | +19.91% | +47.26% | 32.67B | |
| +0.29% | -3.63% | - | - | 16.23B | |
| -0.67% | -2.12% | +26.05% | +117.66% | 16.24B | |
| +0.49% | +0.92% | +4.32% | +22.16% | 14.04B | |
| -1.21% | +3.79% | +78.20% | +28.00% | 13.43B | |
| Average | -0.51% | +2.15% | +78.58% | +109.98% | 29.49B | |
| Weighted average by Cap. | -1.02% | +2.54% | +95.22% | +131.56% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.29M 2.85M 2.67M 2.44M 4.59M 314M 4.66M 31.48M 12.29M 157M 12.35M 12.08M 524M | 2.5M 2.17M 2.03M 1.86M 3.49M 239M 3.55M 23.96M 9.35M 120M 9.4M 9.2M 399M |
| Net income | -14.75M -12.79M -11.99M -10.93M -20.56M -1.41B -20.89M -141M -55.1M -705M -55.38M -54.18M -2.35B | -29.97M -25.97M -24.35M -22.2M -41.77M -2.86B -42.44M -287M -112M -1.43B -112M -110M -4.78B |
| Net Debt | -45.19M -39.17M -36.72M -33.48M -63M -4.31B -64M -432M -169M -2.16B -170M -166M -7.2B | -40.88M -35.44M -33.22M -30.29M -56.99M -3.9B -57.9M -391M -153M -1.95B -153M -150M -6.52B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
